非清髓性HLA全合同胞移植治疗儿童镰状细胞病的多中心前瞻性研究
所有患者初始植入成功,但7例(18.4%)发生继发性植入失败;2年总生存率100%,无事件生存率78.9%,无急慢性GVHD发生。患者报告的健康相关生活质量在移植后1年显著改善。
要点
- 2年总生存率100%,无事件生存率78.9%,无急慢性GVHD。
- 7例(18.4%)发生继发性植入失败,需调整方案降低风险。
- 移植后1年患者报告的健康相关生活质量显著改善。
核心结论
- 该非清髓方案为有HLA全合同胞供者的镰状细胞病儿童提供了相对低毒性的治愈选择,但需调整方案以降低植入失败风险。
主要发现
- 所有患者初始植入成功,但7例(18.4%)在+39天至+391天发生继发性植入失败伴自体血液学重建。
- 移植后2年总生存率100%,无事件生存率78.9%。
- 植入患者2年中位供者髓系嵌合率95%,T细胞嵌合率75%。
- 无患者发生急性或慢性GVHD。
- 血小板输注中位数为0(四分位距0-3)。
临床怎么用
- 对于有HLA全合同胞供者的镰状细胞病儿童,可考虑该非清髓方案作为相对低毒性的治愈选择,但需监测继发性植入失败。
局限性
- 需调整方案以降低植入失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA-identical sibling donor hematopoietic cell transplant (HCT) is an established curative therapy for sickle cell disease (SCD). Although myeloablative HCT conditioning achieves a high event-free survival (EFS) in children, it carries substantial toxicity, including risks of graft-versus-host disease (GVHD), transplant-related mortality, and infertility. Nonmyeloablative conditioning with alemtuzumab, 300 cGy total body irradiation, and sirolimus has demonstrated tolerability as a curative approach in adults with SCD. We conducted a multicenter, prospective clinical trial to evaluate this regimen in children and adolescents with SCD. Thirty-eight patients (aged 2.9-21.9 years; median age, 13.5 years) underwent HCT. All achieved initial engraftment; however, 7 patients (18.4%) experienced secondary graft failure between day +39 and day +391 with autologous hematologic reconstitution. One additional patient received an unconditioned second HCT. At 2 years after HCT, overall survival was 100%, and EFS was 78.9%. Among patients with engraftment, 2-year median donor myeloid chimerism was 95%, and T-cell chimerism was 75%. No patients developed acute or chronic GVHD. The median number of platelet transfusions received was 0 (interquartile range, 0-3). Patient-reported health-related quality of life remained stable early after HCT and significantly improved at 1 year. After year 2, 3 additional patients received a reduced-intensity second HCT to avert secondary graft failure. Although regimen modifications are needed to reduce graft failure risk, this nonmyeloablative approach offers a relatively low-toxicity curative option for children with SCD who have an HLA-identical sibling donor. This trial was registered at www.clinicaltrials.gov as NCT03587272.
引用
- Nickel RS, Abraham A, Chiang KY, et al. Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study. Blood Adv. 2026. PMID: 41945757. doi:10.1182/bloodadvances.2025019567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。